title: Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp.
abstract: BACKGROUND
  Tigecycline has broad spectrum antimicrobial activity and is approved for complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired pneumonia. There are few data on clinical experience of tigecycline in hospital-acquired pneumonia (HAP) and Acinetobacter spp. infection.
  
  
  METHODS
  A retrospective study was performed at eight hospitals in Korea from May 2009 to January 2010. Adult patients treated with tigecycline regardless of their source of infection or pathogens were enrolled.
  
  
  RESULTS
  Tigecycline was administered in 108 patients. Pneumonia was the most common infection (43.5%), followed by skin and soft tissue infections (20.4%). Acinetobacter baumannii was isolated from 83 patients (76.9%) accounting for 50.3% of isolated pathogens, showing a resistance rate of 67.5% to carbapenems. Superinfection was identified in 32 patients (29.6%). Pseudomonas aeruginosa was most common microorganism causing superinfection (46.9%). Overall 30-day mortality rate was 52.9%. Thirty-day mortality rate of HAP and Acinetobacter spp. infection was 60.5% and 59.4%, respectively.
  
  
  CONCLUSIONS
  Tigecycline can be considered as an alternative therapy in patients with HAP or infections caused by Acinetobacter spp., especially extensively drug-resistant A. baumannii.
authors: Division of Infectious Diseases, Samsung Medical Center, Sungkyungkwan University School of Medicine, Seoul, Korea.
authors: Soo-Youn
authors: SY
authors: Moon
authors: Kyong Ran
authors: KR
authors: Peck
authors: Hyun-Ha
authors: HH
authors: Chang
authors: Shin-Woo
authors: SW
authors: Kim
authors: Sang Taek
authors: ST
authors: Heo
authors: Jun Seong
authors: JS
authors: Son
authors: Seong Yeol
authors: SY
authors: Ryu
authors: Chisook
authors: C
authors: Moon
authors: Sook-In
authors: SI
authors: Jung
authors: Sang Yop
authors: SY
authors: Shin
authors: Jeong-a
authors: JA
authors: Lee
authors: Mi-Kyong
authors: MK
authors: Joung
authors: Doo-Ryeon
authors: DR
authors: Chung
authors: Cheol-In
authors: CI
authors: Kang
authors: Jae-Hoon
authors: JH
authors: Song
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015780:Carbapenems / Q000494:pharmacology / Q000627:therapeutic use; D060085:Coinfection; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D000078304:Tigecycline; D018440:beta-Lactam Resistance / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000078304:Tigecycline; D008911:Minocycline